Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients

  80% confidence

• Lilly has been pioneering life-changing discoveries for nearly 150 years

  80% confidence

• Pirtobrutinib is 300 times more selective for BTK versus 98% of other kinases tested in preclinical studies

  80% confidence

• Jaypirca is the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor

  80% confidence

• Continued approval for Jaypirca's MCL and CLL/SLL indications may be contingent upon verification and description of clinical benefit in a confirmatory trial

  80% confidence

• Data from across the pirtobrutinib development program and investigator-led studies reinforce the medicine's unique clinical profile and its potential role across treatment settings and B-cell malignancies

  80% confidence